Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184 in Patients With Mild to Moderate Systemic Lupus Erythematosus

NCT01777256 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT01777256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01777256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184 in Patients With Mild to Moderate Systemic Lupus Erythematosus
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Terminated
Start date
March 1, 2013
Completion date
March 31, 2014
Enrollment
51 (actual)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus